-

Eurofins Scientific Announces the Acquisition of Quasfar, Establishing a Presence in Colombia and Expanding the Presence of Eurofins Laboratories in Latin America

LUXEMBOURG--(BUSINESS WIRE)--The Eurofins network of companies, the global leader in food, environment, pharmaceutical and cosmetic product testing and in discovery pharmacology, forensics, advanced material sciences and agroscience contract research services, announces the completion of the acquisition of Quasfar.

Known as Eurofins Quasfar going forward, the laboratory represents the first Eurofins laboratory in Colombia and is a leading pharmaceutical, veterinary and cosmetic product testing laboratory, with over 26 years of experience, employing over 100 employees. Based in Bogotá, Colombia, the 1,680 m² laboratory is equipped with state-of-the-art testing equipment, technology and information platforms and systems, and is certified in Good Laboratory Practices for pharmaceutical quality control laboratories, under the guidelines of WHO Technical Report Series, No. 957, 2010 44th Report – Annex 1. With a focus on scientific training and R&D, the Quasfar team develops analytical methodologies that respond to customer and regulatory needs, with a commitment to exceptional quality management systems, and good laboratory, bioavailability and bioequivalence practices.

The origins of Eurofins’ presence in Brazil dates back to 2001, when Eurofins Genescan established its presence in Brazil, setting up an office in São Paulo/SP, shortly followed by the opening of a laboratory. Since then, the Eurofins network of companies has continued to expand in Brazil and Latin America, with more than 10 laboratories across 5 LATAM countries now operating across food, environmental, pharmaceutical, agroscience, and clinical diagnostics testing, as well as providing special consultancy services and audits.

With a proven history in providing support to the pharmaceutical sector in Colombia, the acquisition of Quasfar strengthens the Eurofins network’s support to the pharmaceutical industry in Latin America, through the provision of R&D and supporting evaluation in the early stages of pharmaceutical product development, with the highest quality standards and TAT.

Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. With over 61,000 staff across a network of ca. 900 laboratories in 61 countries, Eurofins offers a portfolio of over 200,000 analytical methods.

Eurofins Shares are listed on Euronext Paris Stock Exchange.

Eurofins Quasfar:
Bogotá- based Eurofins Quasfar is a state-of-the-art laboratory, offering a broad analytical testing portfolio to the pharmaceutical, veterinary and cosmetic segments, and recognised for its expertise in developing complex analytical methodologies with diverse techniques to meet customer and regulatory needs.

Contacts

Eurofins Scientific

BOURSE:ERF

Release Versions

Contacts

More News From Eurofins Scientific

The Eurofins Consumer Product Testing Network Completes Significant Laboratory Expansion in Vietnam

HO CHI MINH CITY, Vietnam--(BUSINESS WIRE)--Eurofins Consumer Product Testing Vietnam has completed a major expansion, seeing the laboratory move to a purpose-built 7,000 sq. m laboratory in Ho Chi Minh City. This new facility provides more than two and a half times the floor space of Eurofins Consumer Product Testing Vietnam’s previous site. This investment strengthens the Eurofins Consumer Product Testing network’s capability to deliver world-class testing solutions and supports Vietnam’s rap...

Eurofins: Weekly Report on Share Repurchases From 01st December to 05th December 2025

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins (Paris:ERF): Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 12/01/2025 FR0014000MR3 20 000 58.9527 XPAR EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 12/02/2025 FR0014000MR3 20 000 59.3808 XPAR EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 12/0...

Eurofins Scientific SE: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at 30 November 2025

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (Paris:ERF): ANNEXE B Form to be used for the disclosure of the total number of voting rights and capital, in accordance with the law and grand-ducal regulation of 11 January 2008 on transparency requirements for issuers of securities Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedi (including the issuer ID allocated by the CSSF EUROFINS SCIENTIFIC SE – E1013 Identity of t...
Back to Newsroom